title: Tolerability and safety of the new anti-obesity medications.
abstract: Worldwide obesity prevalence has nearly doubled since 1980. Due to numerous co-morbidities, obesity represents a serious health and socioeconomic problem worldwide. Pharmacotherapy should be an integral part of comprehensive obesity management. Drug therapy can assist in weight loss and its maintenance in those individuals who do not achieve appropriate weight loss through lifestyle interventions alone. After the withdrawal of sibutramine from the market in 2010, orlistat, a lipase inhibitor, was the only remaining prescription drug approved for the long-term treatment of obesity. In 2012, phentermine/topiramate extended-release (PHEN/TPM ER) combination and lorcaserin were approved by the US FDA as novel medications for long-term weight management. Three major phase III trials conducted with each drug confirmed their efficacy in terms of weight loss/maintenance and improvement of cardiometabolic risks. No head-to-head studies between the two new anti-obesity drugs have been carried out. However, in the existing studies PHEN/TPM ER had a superior weight loss profile to lorcaserin but the incidence of adverse effects was lower with lorcaserin. Both drugs were well-tolerated, and adverse events were modest in intensity, dose dependent, rather rare, and tended to decrease with the duration of treatment. Major safety concerns regarding PHEN/TPM ER include elevations in resting pulse rate, teratogenicity, mild metabolic acidosis, and psychiatric and cognitive adverse events. Valvulopathy, cognitive impairment, psychiatric disorders, and hypoglycemia represent major safety concerns for lorcaserin. Although existing trials have not demonstrated any significant issues with PHEN/TPM ER-induced heart rate elevation and lorcaserin-induced valvulopathy, all safety concerns should be seriously taken into account in patients treated with either of these novel anti-obesity medications.
authors.affiliation: Obesity Management Center, Institute of Endocrinology, Národní 8, 116 94, Prague 1, Czech Republic, vhainer@endo.cz.
authors.forename: Vojtech
authors.initials: V
authors.lastname: Hainer
authors.forename: Irena
authors.initials: I
authors.lastname: Aldhoon-Hainerová
mesh_terms: D019440:Anti-Obesity Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001552:Benzazepines / Q000009:adverse effects; D048588:Benzoxazines / Q000009:adverse effects; D016642:Bupropion / Q000009:adverse effects; D002626:Chemistry, Pharmaceutical; D064420:Drug-Related Side Effects and Adverse Reactions; D005632:Fructose / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D052216:Glucagon-Like Peptide 1 / Q000009:adverse effects / Q000031:analogs & derivatives; D006801:Humans; D000069450:Liraglutide; D009271:Naltrexone / Q000009:adverse effects; D009765:Obesity / Q000188:drug therapy*; D010645:Phentermine / Q000008:administration & dosage / Q000009:adverse effects; D000077236:Topiramate
chemical_list: D019440:Anti-Obesity Agents; D001552:Benzazepines; D048588:Benzoxazines; D016642:Bupropion; D000077236:Topiramate; D005632:Fructose; D009271:Naltrexone; C506658:lorcaserin; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1; D010645:Phentermine; C520092:cetilistat
references.citation: Obesity (Silver Spring). 2011 Dec;19(12):2351-60
references.pmid: 21527891
references.citation: Obesity (Silver Spring). 2011 Jan;19(1):110-20
references.pmid: 20559296
references.citation: Int J Obes (Lond). 2012 Jun;36(6):843-54
references.pmid: 21844879
references.citation: Int J Obes (Lond). 2007 Mar;31(3):494-9
references.pmid: 16953261
references.citation: J Hypertens. 2014 Jun;32(6):1178-88
references.pmid: 24621808
references.citation: Cardiovasc Diabetol. 2013 Sep 06;12:130
references.pmid: 24011363
references.citation: Expert Rev Cardiovasc Ther. 2010 Dec;8(12):1777-801
references.pmid: 20707765
references.citation: Lancet. 2010 Aug 21;376(9741):595-605
references.pmid: 20673995
references.citation: N Engl J Med. 2010 Sep 2;363(10):905-17
references.pmid: 20818901
references.citation: Eur J Ophthalmol. 2011 Jul-Aug;21(4):404-9
references.pmid: 21058272
references.citation: Int J Obes (Lond). 2013 Nov;37(11):1443-51
references.pmid: 23812094
references.citation: Lancet. 2011 Apr 16;377(9774):1341-52
references.pmid: 21481449
references.citation: Diabetes Care. 2013 Dec;36(12):4022-9
references.pmid: 24144653
references.citation: N Engl J Med. 2012 Oct 25;367(17):1577-9
references.pmid: 23050510
references.citation: Sleep. 2012 Nov 01;35(11):1529-39
references.pmid: 23115402
references.citation: J Clin Endocrinol Metab. 2011 Oct;96(10):3067-77
references.pmid: 21795446
references.citation: Obesity (Silver Spring). 2014 Mar;22(3):943-9
references.pmid: 23929685
references.citation: Obesity (Silver Spring). 2010 Jan;18(1):108-15
references.pmid: 19461584
references.citation: Obes Facts. 2013;6(5):449-68
references.pmid: 24135948
references.citation: Am J Cardiol. 2013 Apr 15;111(8):1131-8
references.pmid: 23375187
references.citation: Lancet. 2007 Nov 17;370(9600):1706-13
references.pmid: 18022033
references.citation: Diabetes Metab Res Rev. 2012 Dec;28 Suppl 2:8-20
references.pmid: 23280861
references.citation: N Engl J Med. 1997 Aug 28;337(9):602-6
references.pmid: 9271482
references.citation: Am J Obstet Gynecol. 2012 Nov;207(5):405.e1-7
references.pmid: 22917484
references.citation: Expert Opin Drug Saf. 2013 Sep;12(5):741-56
references.pmid: 23738843
references.citation: Diabetes Care. 2007 Feb;30(2):395-402
references.pmid: 17259519
references.citation: Obes Rev. 2010 Dec;11(12):833-4
references.pmid: 21054758
references.citation: Am J Clin Nutr. 2012 Feb;95(2):297-308
references.pmid: 22158731
references.citation: Obesity (Silver Spring). 2012 Feb;20(2):330-42
references.pmid: 22051941
references.citation: N Engl J Med. 2005 Nov 17;353(20):2111-20
references.pmid: 16291981
references.citation: Obesity (Silver Spring). 2012 Jul;20(7):1426-36
references.pmid: 22421927
references.citation: Diabetes Care. 2014 Apr;37(4):912-21
references.pmid: 24103901
references.citation: Obesity (Silver Spring). 2013 May;21(5):935-43
references.pmid: 23408728
references.citation: Diabetes Care. 2004 Jan;27(1):155-61
references.pmid: 14693982
references.citation: Obesity (Silver Spring). 2013 May;21(5):861-4
references.pmid: 23512816
references.citation: Diabetes Metab Syndr Obes. 2013 Apr 08;6:131-9
references.pmid: 23630428
references.citation: J Clin Endocrinol Metab. 2011 Mar;96(3):837-45
references.pmid: 21190985
references.citation: Circ Cardiovasc Imaging. 2013 Jul;6(4):560-7
references.pmid: 23661689
references.citation: Pharmacotherapy. 2006 Mar;26(3):375-87
references.pmid: 16503717
references.citation: Diabetes Care. 2008 Feb;31 Suppl 2:S269-77
references.pmid: 18227496
references.citation: N Engl J Med. 2013 Jul 11;369(2):145-54
references.pmid: 23796131
references.citation: Obesity (Silver Spring). 2013 Nov;21(11):2163-71
references.pmid: 24136928
references.citation: Obes Facts. 2008;1(2):106-16
references.pmid: 20054170
references.citation: Obesity (Silver Spring). 2014 Jan;22(1):5-13
references.pmid: 24307184
references.citation: Int J Obes Relat Metab Disord. 1992 Jun;16(6):397-415
references.pmid: 1322866
references.citation: Epilepsia. 1996 Jun;37(6):539-43
references.pmid: 8641230
references.citation: JAMA. 2000 Apr 5;283(13):1703-9
references.pmid: 10755496
references.citation: World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253
references.pmid: 11234459
references.citation: Int J Obes Relat Metab Disord. 1999 May;23 Suppl 4:S14-8; discussion S18-9
references.pmid: 10385275
references.citation: Appl Ther. 1963 Jun;5:523-4
references.pmid: 13982231
references.citation: N Engl J Med. 2010 Jul 15;363(3):245-56
references.pmid: 20647200